{"id":"subconjunctival-bevacizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival injection/hyperemia"},{"rate":null,"effect":"Subconjunctival hemorrhage"},{"rate":null,"effect":"Eye pain or discomfort"},{"rate":null,"effect":"Anterior chamber inflammation"}]},"_chembl":{"chemblId":"CHEMBL1201583","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"When administered subconjunctivally (injected under the conjunctiva), bevacizumab binds to and neutralizes VEGF, a key driver of pathological neovascularization. This reduces abnormal vessel growth and associated complications in retinal and choroidal diseases. The subconjunctival route provides local ocular delivery while minimizing systemic exposure.","oneSentence":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit abnormal blood vessel formation in the eye.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:09:49.502Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neovascular age-related macular degeneration"},{"name":"Diabetic macular edema"},{"name":"Retinal vein occlusion with macular edema"},{"name":"Corneal neovascularization"}]},"trialDetails":[{"nctId":"NCT06983704","phase":"EARLY_PHASE1","title":"Assessing Combined Bevacizumab-Mitomycin C Use During Ahmed Valve Revision in Recurrent Pediatric Glaucoma","status":"COMPLETED","sponsor":"Benha University","startDate":"2024-02-09","conditions":"Pediatric Glaucoma","enrollment":50},{"nctId":"NCT00555594","phase":"PHASE2, PHASE3","title":"Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization","status":"COMPLETED","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2006-09","conditions":"Corneal Neovascularization","enrollment":18},{"nctId":"NCT05314673","phase":"PHASE4","title":"Preoperative Bevacizumab Injection in Primary Pterygium in Tunisian Patients","status":"COMPLETED","sponsor":"University Hospital Fattouma Bourguiba","startDate":"2019-01-01","conditions":"Pterygium","enrollment":60},{"nctId":"NCT04827836","phase":"NA","title":"Pain Control and Subconjunctival Hemorrhage Size After Intravitreal Injection","status":"COMPLETED","sponsor":"Wolfson Medical Center","startDate":"2021-07-11","conditions":"Intravitreal Injection, Pain, Subconjunctival Hemorrhage","enrollment":100},{"nctId":"NCT02767219","phase":"PHASE3","title":"The Use of Bevacizumab as a Modulator of Wound Healing Following Trabeculectomy Surgery","status":"COMPLETED","sponsor":"Moorfields Eye Hospital NHS Foundation Trust","startDate":"2016-05","conditions":"Glaucoma","enrollment":6},{"nctId":"NCT03037736","phase":"PHASE4","title":"Outpatient Performed Pterygium Surgery Study","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2020-03-01","conditions":"Pterygium of Conjunctiva and Cornea","enrollment":""},{"nctId":"NCT01996826","phase":"PHASE1, PHASE2","title":"A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival","status":"COMPLETED","sponsor":"Reza Dana, MD","startDate":"2014-04","conditions":"Corneal Neovascularization, Corneal Graft Failure","enrollment":75},{"nctId":"NCT01501760","phase":"PHASE3","title":"Efficacy and Safety Study of Avastin to Treat Neovascularisation of the Cornea","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2012-05-13","conditions":"Corneal Newvessels","enrollment":38},{"nctId":"NCT01976923","phase":"PHASE3","title":"Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy","status":"COMPLETED","sponsor":"J. Fernando Arevalo, MD FACS","startDate":"2013-11","conditions":"Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy","enrollment":224},{"nctId":"NCT00853073","phase":"PHASE2, PHASE3","title":"Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?","status":"COMPLETED","sponsor":"Wills Eye","startDate":"2009-02","conditions":"Glaucoma","enrollment":63},{"nctId":"NCT01072357","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival","status":"COMPLETED","sponsor":"Reza Dana, MD","startDate":"2009-12","conditions":"Corneal Neovascularization, Corneal Graft Failure","enrollment":30},{"nctId":"NCT02007174","phase":"","title":"Bevacizumab Injection for Recurrent Pterygium","status":"COMPLETED","sponsor":"Instituto de Oftalmología Fundación Conde de Valenciana","startDate":"2012-03","conditions":"Recurrent Pterygium","enrollment":38},{"nctId":"NCT02530801","phase":"PHASE4","title":"Strategies for Management of Recurrent Pterygium","status":"UNKNOWN","sponsor":"University of Nottingham","startDate":"2017-01","conditions":"Recurrent Pterygium","enrollment":25},{"nctId":"NCT01774474","phase":"PHASE3","title":"PRevention of Macular EDema After Cataract Surgery","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2013-07-10","conditions":"Cystoid Macular Edema, Cataract, Diabetes Mellitus","enrollment":1127},{"nctId":"NCT02901236","phase":"PHASE2, PHASE3","title":"Bevacizumab Versus Mitomycin C as Trabeculectomy Adjuvant in Uncontrolled Glaucoma","status":"COMPLETED","sponsor":"Athens Vision Eye Institute","startDate":"2014-01","conditions":"Glaucoma","enrollment":40},{"nctId":"NCT02796183","phase":"NA","title":"The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Neon Hospital","startDate":"2015-01","conditions":"Diabetic Macular Edema","enrollment":20},{"nctId":"NCT02594423","phase":"PHASE4","title":"Strategies for Management of Corneal Neovascularisation","status":"UNKNOWN","sponsor":"University of Nottingham","startDate":"2015-12","conditions":"Corneal Neovascularisation","enrollment":40},{"nctId":"NCT01640171","phase":"NA","title":"Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival","status":"COMPLETED","sponsor":"Retina Vitreous Associates of Florida","startDate":"2012-07","conditions":"Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema","enrollment":57},{"nctId":"NCT01686529","phase":"PHASE1","title":"Bevacizumab for Primary Pterygium Treatment","status":"COMPLETED","sponsor":"Instituto de Oftalmología Fundación Conde de Valenciana","startDate":"2010-03","conditions":"Pterygium","enrollment":49},{"nctId":"NCT01744756","phase":"PHASE2, PHASE3","title":"Subconjunctival Bevacizumab and Recurrent Pterygium","status":"COMPLETED","sponsor":"Instituto de Olhos de Goiania","startDate":"2012-02","conditions":"Recurrent Pterygium","enrollment":36},{"nctId":"NCT00797303","phase":"PHASE4","title":"The Effect of Bevacizumab on Corneal Neovascularization","status":"COMPLETED","sponsor":"Instituto de Olhos de Goiania","startDate":"2006-01","conditions":"Corneal Neovascularization","enrollment":8},{"nctId":"NCT01425112","phase":"NA","title":"Comparison of Subconjuctival Versus Topical Bevacizumab as Adjunct Therapy to Trabeculectomy","status":"COMPLETED","sponsor":"Sudhalkar Eye Hospital","startDate":"2007-12","conditions":"Complications of Treatment, Progression","enrollment":180},{"nctId":"NCT01310764","phase":"NA","title":"Trabeculectomy With Subconjunctival Bevacizumab Injection","status":"COMPLETED","sponsor":"Rassoul Akram Hospital","startDate":"2009-04","conditions":"Glaucoma","enrollment":36},{"nctId":"NCT01288404","phase":"NA","title":"Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium","status":"COMPLETED","sponsor":"Ramathibodi Hospital","startDate":"2008-01","conditions":"Pterygium of the Conjunctiva and Cornea","enrollment":80},{"nctId":"NCT01122966","phase":"PHASE2, PHASE3","title":"The Effect of Bevacizumab on the Trabeculectomy","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2010-03","conditions":"Glaucoma","enrollment":40},{"nctId":"NCT01128699","phase":"PHASE3","title":"Ahmed Valve Glaucoma Implant With Adjunctive Subconjunctival Bevacizumab in Refractory Glaucoma","status":"UNKNOWN","sponsor":"Vanak Eye Surgery Center","startDate":"2010-05","conditions":"Refractory Glaucoma","enrollment":40},{"nctId":"NCT00992849","phase":"PHASE2","title":"Bevacizumab for the Treatment of Corneal Neovascularization","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2009-05","conditions":"Corneal Neovascularization","enrollment":10},{"nctId":"NCT00854529","phase":"PHASE2","title":"Subconjunctival Bevacizumab Effect on Bleb Vascularity","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2009-04","conditions":"Bleb Vascularity, Bleb Fibrosis, Trabeculectomy Failure","enrollment":60},{"nctId":"NCT00815594","phase":"PHASE4","title":"Bleb Vascularity Change After Subconjunctival Injection Bevacizumab","status":"UNKNOWN","sponsor":"Capital Medical University","startDate":"2008-12","conditions":"Bleb Vascularity, Conjunctival Scarring","enrollment":30},{"nctId":"NCT00681603","phase":"NA","title":"Safety and Effectiveness of Subconjunctival Injection of Bevacizumab in the Treatment of Corneal Neovasculization","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2007-08","conditions":"Lipid Keratopathy, Penetrating Keratoplasty, Herpetic Keratopathy","enrollment":13},{"nctId":"NCT00384631","phase":"NA","title":"Intravitreal Bevacizumab for Neovascular Glaucoma","status":"COMPLETED","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2006-04","conditions":"Neovascular, Glaucoma","enrollment":26},{"nctId":"NCT00468429","phase":"PHASE4","title":"Subconjunctival Bevacizumab to Prevent Bleb Failure After Glaucoma Filtration Surgery","status":"UNKNOWN","sponsor":"Grewal Eye Institute","startDate":"2007-05","conditions":"Glaucoma","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":149,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Subconjunctival Bevacizumab","genericName":"Subconjunctival Bevacizumab","companyName":"Grewal Eye Institute","companyId":"grewal-eye-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit abnormal blood vessel formation in the eye. Used for Neovascular age-related macular degeneration, Diabetic macular edema, Retinal vein occlusion with macular edema.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}